Scientist

Researchers Showcase Their Publications with The Scientist's Journal Club

Retrieved on: 
Monday, January 16, 2023
Molecular biology, Julian Gough (scientist), Doctor of Philosophy, Scientist, Forensic and Scientific Services, Research, Publishing, Journal club

WILMINGTON, Del., Jan. 16, 2023 /PRNewswire-PRWeb/ -- The Scientist proudly launches Journal Club, a webinar series led by our readers that connects researchers to a diverse audience of life scientists. Through Journal Club, scientists have a chance to showcase their recently-published research to The Scientist's readership.

Key Points: 
  • WILMINGTON, Del., Jan. 16, 2023 /PRNewswire-PRWeb/ -- The Scientist proudly launches Journal Club , a webinar series led by our readers that connects researchers to a diverse audience of life scientists.
  • Through Journal Club, scientists have a chance to showcase their recently-published research to The Scientist's readership.
  • The Scientist's Journal Club presents highly innovative molecular biology research conducted by members of our audience.
  • The final presentation will then appear as part of an upcoming Journal Club webinar series.

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Technology, Other Health, Health, General Health, Other Science, Research, Infectious Diseases, Nanotechnology, Genetics, Science, Infection, Severe acute respiratory syndrome coronavirus 2, Transdermal, UCPH Department of Biology, Editorial board, University of Washington Department of Bioengineering, Hepatitis B, NIH, United States Air Force Scientific Advisory Board, CRISPR, Associate, ERC, University, CRS, Internal medicine, Stanford University, Engineer, Degenerative disease, Chair, Pharmaceutics, RNA, Molecular Pharmaceutics, New York Genome Center, Scientist, Ludwig Maximilian University of Munich, Doctor of Philosophy, SNF, MIT, Nervous system, Physiology, BS, Y combinator, Computational linguistics, SAB, MS, PRDS, Drug resistance, JCR, Drug delivery, MIT Department of Brain and Cognitive Sciences, Cognitive science, Medical device, Pharmaceutical industry, Brain, Biology, Carver, List of life sciences, Neuroscience, New York University

Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).

Key Points: 
  • Carver Biosciences, Inc., a biotech company focused on the development of CRISPR/Cas13 antivirals, today announced the formation of its Scientific Advisory Board (SAB).
  • Cameron Myhrvold Ph.D., co-founder of Carver will serve as the chairman of the SAB.
  • Additional appointments include Uri Lopatin, M.D., Olivia Merkel, Ph.D., and Neville Sanjana, Ph.D.
    “I am thrilled to have Dr. Lopatin, Dr. Merkel and Dr. Sanjana join our advisory board,” said Dr. Walter Strapps, co-founder and CEO of Carver.
  • Dr. Sanjana holds a PhD in Brain and Cognitive Sciences from MIT, a BS in Symbolic Systems and a BA in English from Stanford University.

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

Retrieved on: 
Monday, January 9, 2023
Mental Health, Health, Research, Pharmaceutical, Science, Biotechnology, Government, Mental health, Multiple sclerosis, Royal College of Physicians and Surgeons of Canada, Faculty, Associate, CAMH, Drug development, London Olympics, FSD, Neurodegeneration, University Hospitals Plymouth NHS Trust, Neurology, University, Liaquat National Hospital, University of Oxford, Science, Nicotine, DRS, CSE, Neuroscience, University of Bristol, Liver transplantation, Special interest group, Medicine, Scientist, Interest group, European Association for the Study of the Liver, University of Melbourne Faculty of Science, Royal college, Senior, Bachelor of Medicine, Bachelor of Surgery, British, University of Cambridge, FRA, University College London, National Hospital for Neurology and Neurosurgery, Fine chemical, Medical device, Pharmaceutical industry, Philosophy, Neurosurgery, Pharmacology

“We are excited about the incorporation of FSD Pharma Australia, where we have an excellent opportunity to advance our pipeline,” said Mr. Zeeshan Saeed, President of FSD Pharma.

Key Points: 
  • “We are excited about the incorporation of FSD Pharma Australia, where we have an excellent opportunity to advance our pipeline,” said Mr. Zeeshan Saeed, President of FSD Pharma.
  • “Australia is a hotbed for clinical stage biotech companies, and our drug development programs will be able to take advantage of facilities offered by various government incentives in Australia,” added Mr. Saeed.
  • Chataway, Dhanda and Lê have agreed to join our international panel to contribute to our current and new programs,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma.
  • Dr. Chataway received his Bachelor of Medicine & Surgery from Oxford University, and Doctor of Philosophy from Cambridge University.

Seer’s Proteomics Platform Named as Top 10 Innovation in 2022 by The Scientist

Retrieved on: 
Monday, December 12, 2022
Oregon Health & Science University, Seer, SEER, Health, Software, Security (finance), Genomics, Proteomics, Phenotype, Doctor of Philosophy, Biomedical Research, Knight Cancer Institute, Scientist, Research, Disease, Automation, Proteome

Seer’s proprietary-engineered nanoparticle technology is featured amongst pioneers in genomics and sequencing and is the only proteomics technology honored on the list.

Key Points: 
  • Seer’s proprietary-engineered nanoparticle technology is featured amongst pioneers in genomics and sequencing and is the only proteomics technology honored on the list.
  • Seer is a life sciences company developing transformative products that open a new gateway to the proteome.
  • Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures.
  • This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended.

NanoString’s CosMx Spatial Molecular Imager Recognized by The Scientist Magazine as a Top 10 Innovation of 2022

Retrieved on: 
Tuesday, December 13, 2022
Technology, Research, Genetics, Software, Internet, Hardware, Health, Data Management, Science, NanoString Technologies, Gene expression, Scientist, Wake Forest School of Medicine, DSP, Ecosystem, Workflow, Doctor of Philosophy, Protein, MicroRNA, Research, Biology, Cell, Multimedia, Wake Forest University School of Business, Brain, Proteomics, Gene, RNA, Microscope, Medical imaging, Medicine, Technology, Research, Genetics, Software, Internet, Hardware, Health, Data Management, Science

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    CosMx SMI enables high-resolution imaging of more than 1,000 RNA and over 64 protein analytes within morphologically intact whole tissue sections.
  • The CosMx SMI is the newest product in the company's industry-leading spatial analysis portfolio, joining the GeoMx DSP.
  • To learn more about NanoString's CosMx Spatial Molecular Imager, visit www.nanostring.com/CosMx
    NanoString Technologies, a leader in spatial biology , offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology.
  • NanoString, NanoString Technologies, the NanoString logo, CosMx, GeoMx, AtoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Personalis Cancer Assay NeXT Personal Ranks #1 on The Scientist’s Top 10 Innovations of 2022

Retrieved on: 
Monday, December 12, 2022
Software, Other Health, General Health, Networks, Pharmaceutical, Data Management, Oncology, Technology, Hospitals, Clinical Trials, Biotechnology, Medical Supplies, Health, SNV calling from NGS data, Recurrence, Immune system, IPS, Scientist, Intellectual property, Clinical Laboratory Improvement Amendments, Patient, DNA, Cancer, COVID, College of American Pathologists, College, Neoplasm, Drug resistance, Uncertainty, Liquid biopsy, Genomics, Whole genome sequencing, Breast, CRISPR, MRD, Medical imaging, Risk management, Chief Justice of Hungary

Personalis, Inc. today announced its NeXT Personal cancer assay earned the top spot on The Scientists Top 10 Innovations of 2022 list.

Key Points: 
  • Personalis, Inc. today announced its NeXT Personal cancer assay earned the top spot on The Scientists Top 10 Innovations of 2022 list.
  • The Scientists annual Top 10 Innovations list highlights instruments, assays, technologies, and techniques for the life sciences.
  • This shows the broad range considered when assembling and ranking each years list, and the impact of the innovations they have highlighted.
  • Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.

Announcing the Winners of The Scientist's Top 10 Innovations of 2022

Retrieved on: 
Friday, December 16, 2022
NanoString Technologies, Laboratory, Genome, Peptide, Severe acute respiratory syndrome coronavirus 2, Scientist, NeXT, DNA, Research, Disease, News, Chief Justice of Hungary, Single-cell analysis, RNA, Medical device, Fine chemical, Medical imaging, Vaccine

WILMINGTON, Del., Dec. 16, 2022 /PRNewswire-PRWeb/ -- Each year The Scientist highlights the latest and greatest tools, technologies, and techniques to hit the life science landscape. For more than a decade, we've been employing the assistance of expert panels of independent judges who weigh submissions of innovative products that are speeding work in laboratories and facilitating biological discovery.

Key Points: 
  • WILMINGTON, Del., Dec. 16, 2022 /PRNewswire-PRWeb/ -- Each year The Scientist highlights the latest and greatest tools, technologies, and techniques to hit the life science landscape.
  • This year's crop of entries to The Scientist's Top 10 Innovations contest included many with a clinical focus, and others that represent significant advances in sequencing, single-cell analysis, and more.
  • The winners that emerged reflect the fact that the research enterprise continues to hum along as the world emerges from the worst that SARS-CoV-2 threw at us.
  • The winners of The Scientist's Top 10 Innovations of 2022 contest are:
    1.

Good Gaming Inc. To Launch MicroBuddies™ Swarm Defense To Expand Cross Platform Integration For MicroBuddies™ World Experience in Roblox

Retrieved on: 
Tuesday, November 15, 2022
Metaverse, Perception, Lab, Square, Public goods game, Xbox, Weapon, Friends, Scientist, Mobile, Security (finance), Slavery, Defense, Risk, OTCQB, Human, Small-world experiment, Video game, Online shopping, Good, Roblox

Kennett Square, PA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Good Gaming, Inc. (OTCQB: GMER) (the "Company"), an innovative brand creating unique interactive entertainment experiences across the gaming segment since 2008, today announced its plan to launch MicroBuddies Swarm Defense to expand the cross-platform integration for its popular MicroBuddies World Experience in Roblox.

Key Points: 
  • Kennett Square, PA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Good Gaming, Inc. (OTCQB: GMER) (the "Company"), an innovative brand creating unique interactive entertainment experiences across the gaming segment since 2008, today announced its plan to launch MicroBuddies Swarm Defense to expand the cross-platform integration for its popular MicroBuddies World Experience in Roblox.
  • MicroBuddies Swarm Defense will finally give fans of MicroBuddies a chance to experience a section of the back story and have fun developing strategies to eliminate the original hostile Microbuddies to advance to the next challenging round.
  • Players will be able to access MicroBuddies Swarm Defense through a transporter portal in the central lobby of the newly relaunched MicroBuddies World Experience in Roblox.
  • MicroBuddies Swarm Defense connects our cross-platform experiences together by introducing key story elements that form the foundation of MicroBuddies Metaverse or "Buddyverse."

NVIDIA H100 and Quantum-2 Systems Announced Worldwide

Retrieved on: 
Monday, November 14, 2022
Cloud, Universe, Microsoft, Dell, SDK, Azure, H100, Oracle Cloud, Behavior, AI, HPC, GPU, Supermicro, News, SC22, Atos, A100, CUDA, NVDA, Library, Learning, Hybrid-core computing, Microsoft Azure, Weather, DPU, QCT, Graphics processing unit, Scientist, Dell Technologies, Central processing unit, InfiniBand, Nature, Computer graphics, AWS, ASUS, VASP, DOCA, Growth, Organization, Hewlett Packard Enterprise, GTC, Bluefield, Dell PowerEdge, Video game console, Cryptocurrency, Medical device, Lenovo, NVIDIA

DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- SC22 -- NVIDIA today announced broad adoption of its next-generation H100 Tensor Core GPUs and Quantum-2 InfiniBand , including new offerings on Microsoft Azure cloud and 50+ new partner systems for accelerating scientific discovery.

Key Points: 
  • DALLAS, Nov. 14, 2022 (GLOBE NEWSWIRE) -- SC22 -- NVIDIA today announced broad adoption of its next-generation H100 Tensor Core GPUs and Quantum-2 InfiniBand , including new offerings on Microsoft Azure cloud and 50+ new partner systems for accelerating scientific discovery.
  • NVIDIA partners described the new offerings at SC22, where the company released major updates to its cuQuantum, CUDA and BlueField DOCA acceleration libraries, and announced support for its Omniverse simulation platform on NVIDIA A100- and H100-powered systems.
  • Microsoft Azure adoption of the NVIDIA Quantum-2 InfiniBand networking platform follows news of NVIDIA Quantum-2s general availability, announced at GTC in March.
  • Also at SC22, NVIDIA announced that the scientific computing community can use NVIDIA Omniverse on NVIDIA A100 systems and forthcoming NVIDIA H100 systems for a variety of workloads, described in todays press release NVIDIA Omniverse Opens Portals for Scientists to Explore Our Universe .

DarkVision Technologies announced as one of Deloitte’s Technology Fast 50™ program winners for 2022

Retrieved on: 
Wednesday, November 16, 2022
Engineering, Technology, Other Technology, Manufacturing, Software, Hardware, Software, Bachelor of Engineering, Deloitte Technology Fast 500, Central American Technological University, CCI, Council, Creativity, Machine learning, Vector Institute, CBRE, Clean technology, TMX, EDC, Scientist, Entrepreneurship, Computer graphics, Face, Electronics, Growth, Mechanical engineering, Publication, Video game, Management

DarkVision Technologies Inc. received recognition as part of the 2022 Deloitte Technology Fast 50 awards program for its rapid revenue growth, entrepreneurial spirit, and bold innovation.

Key Points: 
  • DarkVision Technologies Inc. received recognition as part of the 2022 Deloitte Technology Fast 50 awards program for its rapid revenue growth, entrepreneurial spirit, and bold innovation.
  • Deloittes Technology Fast 50 program winners consist of public and private companies in the technology sector that are transforming the industry.
  • The program runs alongside the broader Deloitte North American Technology Fast 500, with winners automatically eligible for this elite ranking.
  • The Deloitte Technology Fast 50 program is Canadas pre-eminent technology awards program.